.jpg)
At Diagnopein Nashik, we provide advanced ER-PR-Her-2 testing using the latest immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) techniques.
The ER-PR-Her-2 test is a crucial diagnostic test used for patients with breast cancer. This test checks three major biomarkers: ER (Estrogen Receptor), PR (Progesterone Receptor), and HER-2 (Human Epidermal Growth Factor Receptor 2). These markers play a key role in the growth of breast cancer cells and help oncologists understand the type and aggressiveness of cancer.
The ER-PR-Her-2 test is vital for effective breast cancer treatment. It helps in:
Guiding Treatment Decisions: ER and PR status shows whether hormone therapy will be effective, while HER-2 positivity indicates the need for targeted therapy like trastuzumab.
Predicting Cancer Behavior: Testing these biomarkers gives insight into how aggressive the cancer is and how likely it is to respond to treatment.
Improving Prognosis: Early detection through ER-PR-Her-2 testing allows doctors to personalize treatment plans, increasing the chances of successful therapy.
Monitoring Recurrence Risk: Regular testing helps assess the risk of cancer returning, which is crucial for long-term care.
With ER-PR-Her-2 testing, patients receive personalized treatment, minimizing side effects and enhancing effectiveness.
Accurate and Reliable Results: Our lab uses IHC and FISH techniques for precise detection of ER, PR, and HER-2 markers.
Quick Reporting: Fast and reliable reports enable timely treatment decisions.
Experienced Pathologists: Skilled professionals ensure accurate interpretation of results.
Comprehensive Testing: ER-PR-Her-2 testing can be combined with other diagnostics, including biopsy and blood tests.
Affordable Pricing: High-quality testing at competitive costs makes it accessible to all patients.
Patient-Friendly Process: Our team at Diagnopein Nashik ensures comfort, guidance, and support throughout the testing procedure.
ER-PR-Her-2 testing is performed on a tissue sample obtained from a breast biopsy or surgery. The step-by-step process includes:
Sample Collection: A small tissue sample is collected during biopsy or surgery.
Laboratory Analysis: The sample is processed using IHC for ER and PR detection, and HER-2 is analyzed using IHC or FISH.
Result Interpretation: The pathologist examines staining patterns and percentage of positive cells.
Report Generation: A detailed report shows ER, PR, and HER-2 status and helps guide oncologists for targeted treatment planning.
The test is minimally invasive, safe, and highly informative, helping doctors decide the best treatment pathway for breast cancer patients.
The test evaluates the following key parameters:
Estrogen Receptor (ER) Status: Positive or negative, indicating the likely response to hormone therapy.
Progesterone Receptor (PR) Status: Positive or negative, supporting treatment decisions.
HER-2 (Human Epidermal Growth Factor Receptor 2) Status: Positive or negative; HER-2 positive cancers benefit from targeted therapy.
These parameters are essential for personalized breast cancer treatment and help in monitoring response to therapy.
Patients diagnosed with breast cancer through biopsy or imaging.
Individuals with family history of breast cancer or high-risk genetic factors.
Patients who need guidance for choosing hormone therapy or targeted therapy.
ER-PR-Her-2 testing at Diagnopein Nashik ensures that patients receive evidence-based treatment recommendations.
Advanced Lab Technology: State-of-the-art machines for reliable testing.
Expert Team: Skilled pathologists and technicians ensure accurate results.
Multiple Services: Integration with other diagnostic tests like biopsy, blood panels, and imaging.
Affordable and Transparent: Competitive pricing with clear guidance on test costs.
Convenient Location: Easily accessible Diagnopein Nashik center with patient-friendly facilities.
At Diagnopein Nashik, we combine technology, expertise, and compassionate care to provide the best ER-PR-Her-2 testing services in Nashik.
Biopsies are generally safe but may carry minor risks such as bleeding, infection, or discomfort at the site.
Yes, the test is standard for newly diagnosed breast cancer patients to inform treatment strategies and is typically performed on tumor tissue obtained during a biopsy.
The test is performed on a tumor sample obtained through a biopsy. The sample is analyzed in a lab using techniques like immunohistochemistry (IHC) for ER and PR and fluorescence in situ hybridization (FISH) for Her2.
The test provides critical information for personalized treatment plans, predicting how well a patient may respond to certain therapies, and offering prognostic information about the cancer's aggressiveness.
